Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine
RADA16 is a synthetic peptide that exists as a viscous solution in an acidic formulation. In an acidic aqueous environment, the peptides spontaneously self-assemble into β-sheet nanofibers. Upon exposure and buffering of RADA16 solution to the physiological pH of biological fluids such as blood, int...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-06-01
|
| Series: | Frontiers in Bioengineering and Biotechnology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fbioe.2021.679525/full |
| _version_ | 1818643017470312448 |
|---|---|
| author | Sharanya Sankar Kate O’Neill Maurice Bagot D’Arc Florian Rebeca Marie Buffier Elton Aleksi Melanie Fan Noriaki Matsuda Eun Seok Gil Lisa Spirio |
| author_facet | Sharanya Sankar Kate O’Neill Maurice Bagot D’Arc Florian Rebeca Marie Buffier Elton Aleksi Melanie Fan Noriaki Matsuda Eun Seok Gil Lisa Spirio |
| author_sort | Sharanya Sankar |
| collection | DOAJ |
| description | RADA16 is a synthetic peptide that exists as a viscous solution in an acidic formulation. In an acidic aqueous environment, the peptides spontaneously self-assemble into β-sheet nanofibers. Upon exposure and buffering of RADA16 solution to the physiological pH of biological fluids such as blood, interstitial fluid and lymph, the nanofibers begin physically crosslinking within seconds into a stable interwoven transparent hydrogel 3-D matrix. The RADA16 nanofiber hydrogel structure closely resembles the 3-dimensional architecture of native extracellular matrices. These properties make RADA16 formulations ideal topical hemostatic agents for controlling bleeding during surgery and to prevent post-operative rebleeding. A commercial RADA16 formulation is currently used for hemostasis in cardiovascular, gastrointestinal, and otorhinolaryngological surgical procedures, and studies are underway to investigate its use in wound healing and adhesion reduction. Straightforward application of viscous RADA16 into areas that are not easily accessible circumvents technical challenges in difficult-to-reach bleeding sites. The transparent hydrogel allows clear visualization of the surgical field and facilitates suture line assessment and revision. The shear-thinning and thixotropic properties of RADA16 allow its easy application through a narrow nozzle such as an endoscopic catheter. RADA16 hydrogels can fill tissue voids and do not swell so can be safely used in close proximity to pressure-sensitive tissues and in enclosed non-expandable regions. By definition, the synthetic peptide avoids potential microbiological contamination and immune responses that may occur with animal-, plant-, or mineral-derived topical hemostats. In vitro experiments, animal studies, and recent clinical experiences suggest that RADA16 nanofibrous hydrogels can act as surrogate extracellular matrices that support cellular behavior and interactions essential for wound healing and for tissue regenerative applications. In the future, the unique nature of RADA16 may also allow us to use it as a depot for precisely regulated drug and biopharmaceutical delivery. |
| first_indexed | 2024-12-16T23:52:16Z |
| format | Article |
| id | doaj.art-42fd100e92694f20bbba8adf944b02f7 |
| institution | Directory Open Access Journal |
| issn | 2296-4185 |
| language | English |
| last_indexed | 2024-12-16T23:52:16Z |
| publishDate | 2021-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Bioengineering and Biotechnology |
| spelling | doaj.art-42fd100e92694f20bbba8adf944b02f72022-12-21T22:11:18ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852021-06-01910.3389/fbioe.2021.679525679525Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in BiomedicineSharanya Sankar0Kate O’Neill1Maurice Bagot D’Arc2Florian Rebeca3Marie Buffier4Elton Aleksi5Melanie Fan6Noriaki Matsuda7Eun Seok Gil8Lisa Spirio93-D Matrix Europe SAS, Caluire-et-Cuire, France3-D Matrix UK Ltd., London, United KingdomBLUEPHARM SAS, Paris, France3-D Matrix Europe SAS, Caluire-et-Cuire, France3-D Matrix Europe SAS, Caluire-et-Cuire, France3-D Matrix Inc., Newton, MA, United States3-D Matrix UK Ltd., London, United Kingdom3-D Matrix, Ltd., Tokyo, Japan3-D Matrix Inc., Newton, MA, United States3-D Matrix Inc., Newton, MA, United StatesRADA16 is a synthetic peptide that exists as a viscous solution in an acidic formulation. In an acidic aqueous environment, the peptides spontaneously self-assemble into β-sheet nanofibers. Upon exposure and buffering of RADA16 solution to the physiological pH of biological fluids such as blood, interstitial fluid and lymph, the nanofibers begin physically crosslinking within seconds into a stable interwoven transparent hydrogel 3-D matrix. The RADA16 nanofiber hydrogel structure closely resembles the 3-dimensional architecture of native extracellular matrices. These properties make RADA16 formulations ideal topical hemostatic agents for controlling bleeding during surgery and to prevent post-operative rebleeding. A commercial RADA16 formulation is currently used for hemostasis in cardiovascular, gastrointestinal, and otorhinolaryngological surgical procedures, and studies are underway to investigate its use in wound healing and adhesion reduction. Straightforward application of viscous RADA16 into areas that are not easily accessible circumvents technical challenges in difficult-to-reach bleeding sites. The transparent hydrogel allows clear visualization of the surgical field and facilitates suture line assessment and revision. The shear-thinning and thixotropic properties of RADA16 allow its easy application through a narrow nozzle such as an endoscopic catheter. RADA16 hydrogels can fill tissue voids and do not swell so can be safely used in close proximity to pressure-sensitive tissues and in enclosed non-expandable regions. By definition, the synthetic peptide avoids potential microbiological contamination and immune responses that may occur with animal-, plant-, or mineral-derived topical hemostats. In vitro experiments, animal studies, and recent clinical experiences suggest that RADA16 nanofibrous hydrogels can act as surrogate extracellular matrices that support cellular behavior and interactions essential for wound healing and for tissue regenerative applications. In the future, the unique nature of RADA16 may also allow us to use it as a depot for precisely regulated drug and biopharmaceutical delivery.https://www.frontiersin.org/articles/10.3389/fbioe.2021.679525/fullself-assembling peptide hydrogelnanofiberRADA16hemostasistissue regenerationwound healing |
| spellingShingle | Sharanya Sankar Kate O’Neill Maurice Bagot D’Arc Florian Rebeca Marie Buffier Elton Aleksi Melanie Fan Noriaki Matsuda Eun Seok Gil Lisa Spirio Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine Frontiers in Bioengineering and Biotechnology self-assembling peptide hydrogel nanofiber RADA16 hemostasis tissue regeneration wound healing |
| title | Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine |
| title_full | Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine |
| title_fullStr | Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine |
| title_full_unstemmed | Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine |
| title_short | Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine |
| title_sort | clinical use of the self assembling peptide rada16 a review of current and future trends in biomedicine |
| topic | self-assembling peptide hydrogel nanofiber RADA16 hemostasis tissue regeneration wound healing |
| url | https://www.frontiersin.org/articles/10.3389/fbioe.2021.679525/full |
| work_keys_str_mv | AT sharanyasankar clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine AT kateoneill clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine AT mauricebagotdarc clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine AT florianrebeca clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine AT mariebuffier clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine AT eltonaleksi clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine AT melaniefan clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine AT noriakimatsuda clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine AT eunseokgil clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine AT lisaspirio clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine |